ABOUT

Vir is a science-driven company guided by medical need.

Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Vir is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Vir’s scale and scope, together with leading scientific and management expertise, allow it to perform significant internal R&D, in-license or acquire innovative technology platforms and assets, and fund targeted academic research.

Vir’s initial focus is in three areas of significant unmet need: chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and health-care acquired infections.

The company was founded by Robert Nelsen and ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Sciences, and Alta Partners. Additional investors include the SoftBank Vision Fund, Temasek, Baillie Gifford, the Alaska Permanent Fund, and select sovereign wealth funds, private individuals, family offices, and other institutional investors.

Vir is headquartered in San Francisco, California with operations in Portland, Oregon, Boston, Massachusetts, and Bellinzona, Switzerland

Team

The Vir team is comprised of world leaders in immunology, infectious disease, and drug development. Learn more about our executive team, board of directors, and scientific advisors below.

Executive Team

George Scangos photo

George Scangos, Ph.D.

CEO & Director

Alex Bangs photo

Alex Bangs

Chief Information Officer

Howard Horn photo

Howard Horn

Chief Financial Officer

Michael Kamarck photo

Michael Kamarck, Ph.D.

Chief Technology Officer 

Antonio Lanzavecchia photo

Antonio Lanzavecchia, M.D.

SVP & Senior Research Fellow

Phil Pang photo

Phil Pang, M.D., Ph.D.

SVP, Clinical Development

Jay Parrish photo

Jay Parrish, Ph.D.

Chief Business Officer

Eric Schlezinger photo

Eric Schlezinger

Head of Human Resources

Alpna Seth photo

Alpna Seth, Ph.D.

Chief Operating Officer 

Herbert Virgin photo

Herbert “Skip” Virgin

EVP, Research & Chief Scientific Officer

Board of Directors

George Scangos photo

George Scangos, Ph.D.

CEO & Director

Kristina Burow photo

Kristina Burow

Director

Tom Daniel photo

Tom Daniel, M.D.

Director

Klaus Frueh photo

Klaus Frueh, Ph.D.

Director & Co-founder

Bob More photo

Bob More

Director

Robert Nelsen photo

Robert Nelsen

Director & Co-founder

Deep Nishar Photo

Deep Nishar

Director

Rob Perez photo

Rob Perez

Director

Scientific Advisors

Larry Corey photo

Larry Corey, M.D.

Scientific Advisor & Co-founder

Jeff Bluestone photo

Jeff Bluestone, Ph.D.

Scientific Advisor

Emilio Emini photo

Emilio Emini, Ph.D.

Scientific Advisor

Louis Picker photo

Louis Picker, M.D.

Scientific Advisor & Co-founder

Mark Davis photo

Mark Davis, Ph.D

Scientific Advisor

George Poste photo

George Poste, DVM, Ph.D.

Scientific Advisor

 

 

View All 

 

News

12/18/17
Vir Biotechnology Appoints Leading Immunologist Antonio Lanzavecchia, M.D., Senior Vice President, Senior Research Fellow

SAN FRANCISCO—Vir Biotechnology, Inc. today announced the appointment of Antonio Lanzavecchia, M.D., as Senior Vice President and Senior Research Fellow, effective immediately. Reporting to Chief Executive Officer George Scangos, Ph.D., Dr. Lanzavecchia will provide scientific leadership for Vir’s technical programs that are designed to transform the care of people with serious infectious diseases.

Read More

11/28/17
Vir Biotechnology Appoints Herbert W. “Skip” Virgin Executive Vice President and Chief Scientific Officer

SAN FRANCISCO—Vir Biotechnology, Inc. today announced the appointment of Herbert W. "Skip" Virgin, M.D., Ph.D., as Executive Vice President of Research and Chief Scientific Officer, effective January 1, 2018. Reporting to CEO George Scangos and joining Vir’s management team, Dr. Virgin will lead the company’s significant and growing R&D programs to transform the care of people with serious infectious diseases.

Read More

 

 

View All 

CAREERS at Vir Bio

View Jobs

Vir is always interested in knowing the best and the brightest talent. If you do not see a role that matches your background we encourage you to email your resume to resumes@vir.bio. This will help us find you if a new need arises that fits your experience.

Contact

 

VIR BIOTECHNOLOGY, INC.

499 Illinois Suite 500
San Francisco, CA 94158
email: info@vir.bio